Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with Adriamycin by using a p53-independent pathway

被引:88
作者
Gartenhaus, RB [1 ]
Wang, P [1 ]
Hoffmann, P [1 ]
机构
[1] ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,DEPT PATHOL,DIV HEMATOL ONCOL,NEW HYDE PK,NY 11040
关键词
D O I
10.1073/pnas.93.1.265
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The WAF1/CIP1 protein has been identified as a downstream mediator of the tumor suppressor p53 in regulating cell cycle progression through a G(1)-phase checkpoint. Recent work has implicated the functional status of p53 as a critical determinant in the apoptotic response of certain cell lines to DNA damaging agents. By using human T-cell leukemia virus type I-transformed lymphoid cell lines that differ in their level and function of wild-type p53, we investigated the induction of WAF1/CIP1 and apoptosis after exposure to Adriamycin, a genotoxic agent. We found that regardless of the p53 status in these cell lines, WAF1/CIP1 RNA was rapidly induced in response to Adriamycin treatment. An elevated level of WAF1/CIP1 protein was observed as well. Additionally, we demonstrated that apoptosis was induced in all cell lines analyzed despite some having functionally inactive p53 protein. Our data suggest that a p53-independent pathway may play a role in the apoptotic response observed in some cell lines after exposure to DNA damaging agents.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 24 条
[1]   EXPRESSION OF ALTERNATIVELY SPLICED HUMAN T-LYMPHOTROPIC VIRUS TYPE-I PX MESSENGER-RNA IN INFECTED CELL-LINES AND IN PRIMARY UNCULTURED CELLS FROM PATIENTS WITH ADULT T-CELL LEUKEMIA LYMPHOMA AND HEALTHY CARRIERS [J].
BERNEMAN, ZN ;
GARTENHAUS, RB ;
REITZ, MS ;
BLATTNER, WA ;
MANNS, A ;
HANCHARD, B ;
IKEHARA, O ;
GALLO, RC ;
KLOTMAN, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :3005-3009
[2]  
COLE SPC, 1986, CANCER CHEMOTH PHARM, V17, P259
[3]   CHEMOTHERAPY FOR LARGE-CELL LYMPHOMA - OPTIMISM AND CAUTION [J].
COLEMAN, M .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) :140-142
[4]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[5]  
FAN SJ, 1994, CANCER RES, V54, P5824
[6]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[7]  
GARTENHAUS RB, 1991, BLOOD, V78, P2956
[8]  
GARTENHAUS RB, 1996, IN PRESS LEUKEMIA
[9]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[10]   A SELECTIVE PROCEDURE FOR DNA EXTRACTION FROM APOPTOTIC CELLS APPLICABLE FOR GEL-ELECTROPHORESIS AND FLOW-CYTOMETRY [J].
GONG, JP ;
TRAGANOS, F ;
DARZYNKIEWICZ, Z .
ANALYTICAL BIOCHEMISTRY, 1994, 218 (02) :314-319